Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term Extension of Ulviprubart in Inclusion Body Myositis
NCT06450886Phase 3Active, not recruiting
- Sponsor
- Abcuro
- Start
- Oct 2024
- Primary completion
- Jan 2029
- Modality
- Monoclonal Antibodies
- Countries
- 2
01
Overview
Phase 3, open-label, single-arm trial of ulviprubart in inclusion body myositis (IBM), sponsored by Abcuro. Started Oct 2024; status: active, not recruiting.
02
Drugs
ulviprubart
03
Conditions
inclusion body myositis (IBM)
Beyond the preview
Go deeper on NCT06450886.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06450886.